IMVT / Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab

Tuesday, Immunovant announced early-stage trial results for an autoimmune disease candidate that caused its shares to rocket higher. Investors are bid more_horizontal

Although Immunovant's stock has rallied around 100% since January, recent data on its therapeutic candidate, IMVT-1402, has further bolstered confiden more_horizontal

Immunovant (IMVT) shares virtually doubled on Tuesday after the biopharmaceutical company reported positive results from a Phase 1 trial of its experi more_horizontal

Immunovant reported positive phase 1 trial data for IMVT-1402. The company said the therapy showed a strong safety profile and fewer side effects than more_horizontal

There was a bumper boost for stock in two Nasdaq-listed biotechs premarket after an experimental antibody treatment was revealed to have blockbuster p more_horizontal

Markets moved lower on Tuesday, giving up some gains from Monday. Immunovant released positive trial data that sent its shares soaring. more_horizontal

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives f more_horizontal

Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments. more_horizontal